

**Next Day Disclosure Return**  
(Equity issuer - changes in issued share capital and/or share buybacks)

Name of listed issuer: Dawnrays Pharmaceutical (Holdings) Ltd.Stock code: 2348Date submitted: 3 December 2019

Section I must be completed by a listed issuer where there has been a change in its issued share capital which is disclosable pursuant to rule 13.25A of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Exchange").

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is disclosable under rule 10.06(4)(a).

Description of securities: Ordinary Shares of HK\$0.05 each

I.					
Issues of shares (Notes 6 and 7)	No. of shares	Issued shares as a % of existing number of issued shares before relevant share issue (Notes 4, 6 and 7)	Issue price per share (Notes 1 and 7)	Closing market price per share of the immediately preceding business day (Note 5)	% discount/ premium of issue price to market price (Note 7)
Opening balance as at (Note 2) 2 December 2019	1,564,910,000				
(Note 3)					
Share repurchases on 4 October 2019 but not yet cancelled	82,000				
Share repurchases on 8 October 2019 but not yet cancelled	527,000				
Share repurchases on 10 October 2019 but not yet cancelled	154,000				
Share repurchases on 11 October 2019 but not yet cancelled	363,000				
Share repurchases on 14 October 2019 but not yet cancelled	234,000				
Share repurchases on 15 October 2019 but not yet cancelled	98,000				
Share repurchases on 16 October 2019 but not yet cancelled	393,000				
Share repurchases on 17 October 2019 but not yet cancelled	290,000				
Share repurchases on 18 October 2019 but not yet cancelled	310,000				

Share repurchases on 21 October 2019 but not yet cancelled	160,000			
Share repurchases on 22 October 2019 but not yet cancelled	170,000			
Share repurchases on 23 October 2019 but not yet cancelled	240,000			
Share repurchases on 24 October 2019 but not yet cancelled	270,000			
Share repurchases on 25 October 2019 but not yet cancelled	48,000			
Share repurchases on 28 October 2019 but not yet cancelled	200,000			
Share repurchases on 29 October 2019 but not yet cancelled	100,000			
Share repurchases on 30 October 2019 but not yet cancelled	218,000			
Share repurchases on 31 October 2019 but not yet cancelled	68,000			
Share repurchases on 1 November 2019 but not yet cancelled	100,000			
Share repurchases on 4 November 2019 but not yet cancelled	210,000			
Share repurchases on 5 November 2019 but not yet cancelled	185,000			
Share repurchases on 6 November 2019 but not yet cancelled	257,000			
Share repurchases on 7 November 2019 but not yet cancelled	190,000			
Share repurchases on 8 November 2019 but not yet cancelled	180,000			
Share repurchases on 11 November 2019 but not yet cancelled	100,000			
Share repurchases on 12 November 2019 but not yet cancelled	230,000			
Share repurchases on 14 November 2019 but not yet cancelled	170,000			
Share repurchases on 15 November 2019 but not yet cancelled	70,000			
Share repurchases on 18 November 2019 but not yet cancelled	120,000			

Share repurchases on 19 November 2019 but not yet cancelled	216,000			
Share repurchases on 20 November 2019 but not yet cancelled	212,000			
Share repurchases on 21 November 2019 but not yet cancelled	260,000			
Share repurchases on 22 November 2019 but not yet cancelled	420,000			
Share repurchases on 25 November 2019 but not yet cancelled	260,000			
Share repurchases on 26 November 2019 but not yet cancelled	262,000			
Share repurchases on 27 November 2019 but not yet cancelled	210,000			
Share repurchases on 28 November 2019 but not yet cancelled	387,000			
Share repurchases on 29 November 2019 but not yet cancelled	220,000			
Share repurchases on 2 December 2019 but not yet cancelled	145,000			
Share repurchases on 3 December 2019 but not yet cancelled	260,000	0.0166%		
Closing balance as at (Note 8) 3 December 2019	1,564,910,000			

We hereby confirm to the best knowledge, information and belief that, in relation to each issue of securities as set out in Section I, it has been duly authorized by the board of directors of the listed issuer and, insofar as applicable: (Note 9)

- (i) all money due to the listed issuer in respect of the issue of securities has been received by it;
- (ii) all pre-conditions for the listing imposed by the Listing Rules under “Qualifications of listing” have been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical (Note 10);
- (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;
- (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
- (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
- (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

*Notes to Section I:*

1. *Where shares have been issued at more than one issue price per share, a weighted average issue price per share should be given.*
2. *Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to rule 13.25A or Monthly Return pursuant to rule 13.25B, whichever is the later.*
3. *Please set out all changes in issued share capital requiring disclosure pursuant to rule 13.25A together with the relevant dates of issue. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.*
4. *The percentage change in the number of issued shares of listed issuer is to be calculated by reference to the listed issuer's total number of shares in issue (excluding for such purpose any shares repurchased or redeemed but not yet cancelled) as it was immediately before the earliest relevant event which has not been disclosed in a Monthly Return or Next Day Disclosure Return.*
5. *Where trading in the shares of the listed issuer has been suspended, "closing market price per share of the immediately preceding business day" should be construed as "closing market price per share of the business day on which the shares were last traded".*
6. *In the context of a repurchase of shares:*
  - *"issues of shares" should be construed as "repurchases of shares"; and*
  - *"issued shares as a % of existing number of shares before relevant share issue" should be construed as "repurchased shares as a % of existing number of shares before relevant share repurchase".*
7. *In the context of a redemption of shares:*
  - *"issues of shares" should be construed as "redemptions of shares";*
  - *"issued shares as a % of existing number of shares before relevant share issue" should be construed as "redeemed shares as a % of existing number of shares before relevant share redemption"; and*
  - *"issue price per share" should be construed as "redemption price per share".*
8. *The closing balance date is the date of the last relevant event being disclosed.*
9. *Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases.*
10. *"Identical" means in this context:*
  - *the securities are of the same nominal value with the same amount called up or paid up;*
  - *they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and*
  - *they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.*

## II.

## A. Purchase report

Trading date	Number of securities purchased	Method of purchase (Note)	Price per share or highest price paid \$	Lowest price paid \$	Total paid \$
3-12-2019	<u>260,000</u>	On the Exchange	HK\$1.43	HK\$1.41	<u>HK\$370,720.00</u>
Total	<u>260,000</u>				<u>HK\$370,720.00</u>

## B. Additional information for issuer whose primary listing is on the Exchange

1.	Number of such securities purchased on the Exchange in the year to date (since ordinary resolution)	(a) <u>30,061,000</u>
2.	% of number of shares in issue at time ordinary resolution passed acquired on the Exchange since date of resolution	<u>1.8949%</u>
	$\frac{((a) \times 100)}{1,586,382,000}$	

We hereby confirm that the repurchases set out in A above which were made on the Exchange were made in accordance with the Listing Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated 16 April 2019 which has been filed with the Exchange. We also confirm that any purchases set out in A above which were made on another stock exchange were made in accordance with the domestic rules applying to purchases made on that other exchange.

Note to Section II: Please state whether on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.

Submitted by: Pang Kit Ling

(Name)

Title: Secretary  
(Director, Secretary or other duly authorised officer)